Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKOVE-1: NVL-655 in advanced ALK-positive NSCLC and other solid tumors
NL-OMON60336Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of neladalkib in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (7 arms), sponsored by Nuvalent. Primary endpoints: Safety and tolerability, RP2D and MTD and 1 more. Started May 2024; status: recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60336.